Phase 2 N=71 Vitamin D to ENhance TraUma REcovery
Musculoskeletal Pain
Primary: Chronic Pain Severity — 4.33; 5; 4.39; 4.22 score on a scale — p=0.83
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=38 Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
Endometrial Cancer
Primary: Evaluate Patients With Progression Free Survival (PFS) — 26 months
Phase 2 N=286 Efficacy and Safety of XT-150 in Osteoarthritis of the Knee
Osteoarthritis, Knee
Primary: Stage A: Number of Participants Achieving 30% Improvement From Baseline in Western Ontario and McMasters Arthritis Index (WOMAC) Pain Score — 26; 28; 38; 53 Participants
Phase 2 N=38 Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome
Hyperphagia in Prader-Willi Syndrome
Primary: Change From Baseline in Hyperphagia in Prader-Willi Syndrome (PWS) Questionnaires- Responsiveness (HPWSQ-R) Total Score at End-of-treatment (Day 15) — -15.6; -8.9 score…
Phase 2 N=33 Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2
Macular Telangiectasia Type 2
Primary: Frequency of Ocular and/or Non-ocular Treatment Emergent Adverse Events — 26; 26; 6; 13 Participants
Phase 2 N=45 BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
Pancreatic Cancer
Primary: Treatment Response — 0; 0; 0; 0 participants
Phase 2 N=160 Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)
Compensated Cirrhosis · Nonalcoholic Steatohepatitis
Primary: Change From Baseline in Enhanced Liver Fibrosis Score at Week 48 — -0.071; 0.125; -0.213; 0.263 score on a scale
Phase 2 N=59 Memory and Antioxidants in Vascular Impairment Trial
Vascular Cognitive Impairment no Dementia
Primary: Change in Executive Function — 0.32; 0.36 z-score
Phase 2 N=448 Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)
Acute Respiratory Distress Syndrome · Coronavirus Infection
Primary: Number of Participants Who Are Classified 8 (Dead), 7 (Hospitalized, on Invasive Mechanical Ventilation or ECMO), or 6 (Hospitalized, on Non-invasive Ventilation or High…
Phase 2 N=17 Spironolactone Therapy In Young Women With NASH
NASH - Nonalcoholic Steatohepatitis
Primary: Change in Liver Stiffness on Magnetic Resonance Elastography (MRE) — 0.025; -0.265; 0.105; 0.135 Change in kPA
Phase 2 N=233 A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
Lipoprotein Disorder
Primary: Percent Change From Baseline in Lp(a) - Assessed Via Intact Lp(a) Assay — -47.35; -81.57; -85.71; 0.48 Percent change — p=<.001
Phase 2 N=84 Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
Advanced Solid Tumors
Primary: Part 1: Number of Participants With Dose Limiting Toxicities (DLTs) — 0 Participants
Phase 2 N=43 Prevention of Postpartum Hemorrhage With Tranexamic Acid
Postpartum Hemorrhage
Primary: PK Model Parameter Estimates — 8.85; 10.39; 9.45 L/hr
Phase 2 N=25 LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
Glioblastoma · Recurrent Glioblastoma · Supratentorial Glioblastoma
Primary: Objective Response Rate (ORR) — 0 participants
Phase 2 N=48 Semaglutide for Alcohol Use Disorder
Alcohol Use Disorder · Cigarette Smoking
Primary: Change in Alcohol Consumed — -32.72; -6.95 grams